Cargando…

Novel coronavirus disease in patients with end‐stage kidney disease

The novel coronavirus disease outbreak started in Wuhan, China, in December 2019 and has since spread rapidly worldwide. As almost all patients with end‐stage kidney disease have been treated with HD in Japan, they have a higher risk of infection than the healthy population. Moreover, the complicati...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimada, Noriaki, Shimada, Hiroaki, Itaya, Yoshiaki, Tomino, Yasuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7675310/
https://www.ncbi.nlm.nih.gov/pubmed/33040443
http://dx.doi.org/10.1111/1744-9987.13599
_version_ 1783611656331329536
author Shimada, Noriaki
Shimada, Hiroaki
Itaya, Yoshiaki
Tomino, Yasuhiko
author_facet Shimada, Noriaki
Shimada, Hiroaki
Itaya, Yoshiaki
Tomino, Yasuhiko
author_sort Shimada, Noriaki
collection PubMed
description The novel coronavirus disease outbreak started in Wuhan, China, in December 2019 and has since spread rapidly worldwide. As almost all patients with end‐stage kidney disease have been treated with HD in Japan, they have a higher risk of infection than the healthy population. Moreover, the complications of renal failure, such as hypertension and cardiovascular diseases, appear to be a risk factor of death owing to novel coronavirus disease. The reported morbidity and mortality rates of novel coronavirus disease are significantly higher in dialysis patients than in the healthy population. No treatment for novel coronavirus disease has yet been developed; thus, countermeasures to prevent the spread of coronavirus disease in dialysis facilities must be rapidly established. The latest findings on novel coronavirus disease in patients with end‐stage kidney disease and the guidelines for countermeasures against the spread of novel coronavirus disease worldwide are summarized in this review.
format Online
Article
Text
id pubmed-7675310
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-76753102020-11-19 Novel coronavirus disease in patients with end‐stage kidney disease Shimada, Noriaki Shimada, Hiroaki Itaya, Yoshiaki Tomino, Yasuhiko Ther Apher Dial Review The novel coronavirus disease outbreak started in Wuhan, China, in December 2019 and has since spread rapidly worldwide. As almost all patients with end‐stage kidney disease have been treated with HD in Japan, they have a higher risk of infection than the healthy population. Moreover, the complications of renal failure, such as hypertension and cardiovascular diseases, appear to be a risk factor of death owing to novel coronavirus disease. The reported morbidity and mortality rates of novel coronavirus disease are significantly higher in dialysis patients than in the healthy population. No treatment for novel coronavirus disease has yet been developed; thus, countermeasures to prevent the spread of coronavirus disease in dialysis facilities must be rapidly established. The latest findings on novel coronavirus disease in patients with end‐stage kidney disease and the guidelines for countermeasures against the spread of novel coronavirus disease worldwide are summarized in this review. John Wiley & Sons Australia, Ltd 2020-10-27 2021-10 /pmc/articles/PMC7675310/ /pubmed/33040443 http://dx.doi.org/10.1111/1744-9987.13599 Text en © 2020 The Authors. Therapeutic Apheresis and Dialysis published by John Wiley & Sons Australia, Ltd on behalf of International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society for Dialysis Therapy. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Review
Shimada, Noriaki
Shimada, Hiroaki
Itaya, Yoshiaki
Tomino, Yasuhiko
Novel coronavirus disease in patients with end‐stage kidney disease
title Novel coronavirus disease in patients with end‐stage kidney disease
title_full Novel coronavirus disease in patients with end‐stage kidney disease
title_fullStr Novel coronavirus disease in patients with end‐stage kidney disease
title_full_unstemmed Novel coronavirus disease in patients with end‐stage kidney disease
title_short Novel coronavirus disease in patients with end‐stage kidney disease
title_sort novel coronavirus disease in patients with end‐stage kidney disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7675310/
https://www.ncbi.nlm.nih.gov/pubmed/33040443
http://dx.doi.org/10.1111/1744-9987.13599
work_keys_str_mv AT shimadanoriaki novelcoronavirusdiseaseinpatientswithendstagekidneydisease
AT shimadahiroaki novelcoronavirusdiseaseinpatientswithendstagekidneydisease
AT itayayoshiaki novelcoronavirusdiseaseinpatientswithendstagekidneydisease
AT tominoyasuhiko novelcoronavirusdiseaseinpatientswithendstagekidneydisease